Abstract
Anna Lisa Iorio1, Martina da Ros1, Lorenzo Genitori1, Maurizio Lucchesi1, Fabiana Colelli2, Giacomo Signorino2, Francesco Cardile2, Giacomo Laffi3, Maurizio de Martino1, Claudio Pisano2 and Iacopo Sardi1
1Neuro-Oncology Unit, Department of Pediatric Oncology, Meyer Children’s Hospital, Florence, Italy
2BIOGEM Research Institute, Ariano Irpino, Italy
3Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Correspondence to:
Iacopo Sardi, email: [email protected]
Keywords: temozolomide, glioblastoma, morphine, blood-brain barrier, animal model
Received: November 15, 2016 Accepted: July 13, 2017 Published: August 03, 2017
ABSTRACT
Despite multimodal treatments comprising, radiation therapy (RT) and chemotherapy with temozolomide (TMZ), the prognosis of glioblastoma multiforme (GBM) remains dismal and consolidated therapy yields a median survival of 14.6 months.
Blood Brain Barrier (BBB) mediated chemoresistance and high dose related toxicity make necessary the development of new therapeutic approach to sensitize GBM to TMZ.
The aim of the present study was to investigate the potential of the treatment morphine plus TMZ metronmic doses (1,77 and 0,9 mg/kg) in GBM therapy.
The effect of morphine, on tumor cell growth and P-glycoprothein (P-gp) activity, was investigate in in vitro models.
The results demonstrated that GBM cells growth is not influenced by morphine treatment and, for the first time, we show that morphine is an inhibitor of the activity of P-gp efflux transporter who is markedly expressed on BBB.
In vivo, response to the treatments TMZ plus morphine was investigated in an orthotopic nude mice model of GBM.
Animals treated with TMZ metronomic doses showed a significant tumor growth inhibition compared to untreated mice and association with morphine appears to improve TMZ efficacy.
Moreover, the combination of morphine with lower dose of TMZ result in a cytostatic effect on tumor growth over the period of the pharmacological treatments.
In conclusion this novel approach could be a successful strategy to overcome chemoresistance and side effects TMZ mediated, reducing drug dosage and improving long term response, in GBM therapy.
INTRODUCTION
GBM is the most common and aggressive primary brain tumor derived from glial progenitors of the central nervous system (CNS) [1, 2].
TMZ, the current standard care for GBM [3, 4], shows chemoresistance shortly after the initiation of treatment [5]; patients median survival is about 12–18 months and only 3 % survive longer than 5 years [6].
Resistance to TMZ has shown to be multifactorial, including changes in the cell cycle, up regulation of mismatch repair genes and MGMT [7] and additional TMZ resistance mechanisms involving P-gp expression, modulation and activity have been recently reported [8, 9, 10].
P-gp belongs to the ATP binding cassette (ABC) transporters and plays the major role in the failure of cancer therapy, limiting the accumulation of a wide range of molecules in numerous tissue including the brain [11].
Different studies have shown that brain concentrations of TMZ are only 17–20 % of the blood levels [12, 13] and TMZ’s dose limiting toxicity of leukopenia and thrombocytopenia, with a possible increased risk of opportunistic infections, precludes the use of higher doses which theoretically could result in higher intratumoral concentrations.
It was also reported that antitumor activity of TMZ is highly schedule-dependent [14, 15]; many experimental and preclinical studies suggested that in vivo frequent administration of low doses of chemotherapeutic drugs, known as metronomic chemotherapy, could affect tumor endothelium and inhibit tumor angiogenesis, reducing significant side effects [16].
Basing on literature data regarding the pharmacological modulation of BBB by morphine [17], the most commonly used opioid in oncological patients, we have recently demonstrated that this agent is able to increase delivery and efficacy of doxorubicin (Dox) in animal models, without increasing systemic toxicities [18, 19, 20, 21].
However, results about the effect of morphine on tumor cells are numerous and often controversial.
Some authors reported that morphine can reduce the efficacy of chemotherapy, stimulating tumor cell growth in brain, breast and renal cancer [22, 23, 24, 25]. Other reported that the association of morphine with chemotherapeutic agents result in an improved antitumor effect and suppression of cancer cells proliferation [26, 27]
Considering all this findings, the aim of the present study was further investigate the effect of morphine on tumor cells and explore the potential of combined treatments morphine plus TMZ in GBM therapy, in order to overcome chemoresistance and side effects TMZ mediated.
RESULTS
Effect of morphine on GBM cells proliferation
We tested the modulatory action of morphine on tumor cells growth treating two human GBM cell lines (U87MG and A172) with different doses of morphine (10, 20, 40 μM) for 24 and 48 hours.
As show in Figure 1, no difference in cell proliferation, at 24 hours, can be observed comparing control groups and morphine treated groups, in both cell lines. Data were confirmed comparing treated groups vs control groups after 48 hours of treatment, in both cell lines.
Figure 1: Effect of morphine on human GBM cells growth. U87MG and A172 cells were treated with various concentrations of morphine for 24 and 48 hours. No changes in cell growth can be observed comparing controls vs all morphine dosages, in both cell lines and times. Data were expressed as mean ± SD.
Effect of morphine on ATPase activity of P-gp
The drug efflux function of P-gp is coupled to ATP hydrolysis, which is stimulated in the presence of P-gp substrates.
Our data indicated that the ATP concentration measured in samples treated with different concentration of morphine are significantly higher compared to Verapamil samples (*p< 0,01) (Figure 2A), indicating that in presence of morphine there was a reduced consumption of ATP.
Figure 2: Interaction between morphine and P-gp ATPase activity. (A) After 40 min of incubation with various concentrations of morphine, the remaining unmetabolized ATP was detected as a luciferase-generated luminescent signal. Statistical differences can be observed comparing ATP concentration of Verapamil vs all doses of TC (*p<0,01). Data were expressed as mean ± SD. (B) ATP consumption reflected P-gp ATPase activity. In presence of morphine the function of the efflux transporter was lower than NT and Verapamil, indicating that morphine is a functional inhibitor of P-gp. Data were expressed as mean ± SD.
To assess the effect of morphine on the P-gp ATPase activity, P-gp-mediated ATP hydrolysis was measured, with the appropriate formula reported in materials and method section, using ATP concentration of morphine and sodium orthovanadate samples. As shown in Figure 2B, all morphine doses are able to reduce the ATPase activity of P-gp.
Effect of combined treatment TMZ plus morphine on tumor growth in glioblastoma xenograft
Basing on literature data reporting that TMZ metronomic administrations are more effective than a single bolus dose [14], a preliminary experiment was realized to evaluate TMZ concentration for treatments.
Animals were treated daily with TMZ (1,77-2,66 and 4 mg/kg) for five weeks and tumor growth was monitored trough weekly BLI acquisition.
Data shown in Figure 3 revealed that all TMZ doses were effective in tumor growth inhibition compared to control (p<0,05) so 1,77 mg/kg, the lowest concentration that achieved a significant results, were chosen as dosage for next experiments.
Figure 3: BLI average radiance throughout the experimental time. Statistical significant differences were observed comparing BLI Averageradiance of control group vs all TMZ treated groups (p<0,05). Physiological solution 5 ml/kg (violet line), TMZ 1,77 mg/kg (blue line), TMZ 2,66 mg/kg (red line), and TMZ 4 mg/kg (green line). Data were expressed as mean ± SD.
The first step experiment was then performed combining TMZ treatment (1,77 mg/kg) with morphine (10 mg/kg) [16-20].
One week after tumor implantation, animals were divided in four groups and treated following the first step experiment’s schedule as described in materials and methods section. Time-course and bioluminescence (BLI) evaluation of tumor growth are reported in Figure 4.
Figure 4: BLI average radiance curves distinctly for group of treatment and days of treatment. Atday +42, morphine treatment (red) is not associated with an increased tumor growth compared to control group (black) while statistically significant differences (**p<0,01) were found between vehicle group vs TMZ 1,77 mg/kg group (green) and TMZ 1,77 mg/kg plus morphine 10 mg/kg group (blue). Data were expressed as mean ± SD.
Statistical significant results were obtained comparing BLI data of treated groups vs control group, at days +28, +35 and +42. At day +28 the BLI Average Radiance of control group was 2,81E+05 vs 3,67E+04 of TMZ group (**p<0,01) and 2,97E+04 of TMZ plus morphine group (**p<0,01). BLI Average Radiance of control group, at day +35, was 8,71E+05 vs 3,68E+04 of TMZ group (***p<0,001) and 2,58E+04 of TMZ plus morphine group (***p<0,001). On the last BLI acquisition, day +42, the Average Radiance of control group was 1,10E+06 vs 4,70E+04 of TMZ group (**p<0,01) and 1,95E+04 of TMZ plus morphine group (**p<0,01) (Figure 5). At day +42 two animals of control group died before BLI acquisition.
Figure 5: Therapeutically effect of TMZ metronomic treatments. TMZ 1,77 mg/kg, whit or without morphine, is effective in tumor growth inhibition from early administration and not only at the end of the experiment as cumulative doses effect. Statistical analysis wasperformed, at day +28,+35 and +42, between vehicle group (black), TMZ 1,77 mg/kg group (green) and TMZ 1,77 mg/kg plus morphine 10 mg/kg group (blue) (**p<0,01, ***p<0,001). Data were expressed as mean ± SD.
This data indicated that TMZ metronomic treatments have significant effect, from day +28 to day +42, on tumor growth but, analyzing the global trends of tumor regression, the BLI Average Radiance of TMZ plus morphine group was 2.5 fold lower than value observed in TMZ group (Figure 6). No differences in body weight loss were observed comparing control group vs all treated groups (Figure 7).
Figure 6: BLI average radiance curves distinctly for groups and days of treatment. TMZ (1,77 mg/kg) shows an important effect in combination with morphine (10 mg/kg), determining a BLI reduction of 2,5 fold compared to BLI measured in group treated with only TMZ (1,77 mg/kg). Data were expressed as mean ± SD.
Figure 7: Body weight evaluation throughout the experimental time. Side effects of treatments were evaluated in terms of body weight variation. No statistical significant differences were reported between all different groups, indicating that the improved antitumor activity of TMZ plus morphine treatment was not associate to an increased systemic toxicity. Data were expressed as mean ± SD.
Effect of morphine in combination with lower dose of TMZ
We also investigated if combined treatment with morphine could make possible further reduction of TMZ dose, preserving the therapeutically effect of the alkylating agent.
To test this hypothesis, the second step experiment was performed comparing the effect of an half dose of TMZ (0,9 mg/kg), with or without morphine, vs TMZ (1,77 mg/kg).
One week after tumor implantation, animals were divided in four groups and treated following the second step experiment’s schedule as described in materials and methods section.
Statistical significant results were obtained comparing BLI data of treated groups and control group at the end of the treatments (day +42).
The BLI Average Radiance of control group was 4,55E+05 vs 1,12E+04 of TMZ (1,77 mg/kg) group (****p<0,0001), 5,51E+04 of TMZ (0,9 mg/kg) group (***p<0,001) and 6,98E+04 of TMZ (0,9 mg/kg) plus morphine group (****p<0,0001) (Figure 8A).
Figure 8: BLI signals throughout the experimental time. (A) Statistical analysis was performed between vehicle and the other experimental groups (****p<0,0001; ***p<0,001). Data were expressed as mean ± SD. (B) Side effects of treatments were evaluated in terms of body weight variation. No statistical significant difference were reported between all different groups. Data were expressed as mean ± SD.
At the end of the treatments (day +42), TMZ (1.77 mg/kg) determined a tumor volume inhibition (TVI%, reported as BLI reduction and calculated comparing BLI value with BLI of control group treated with vehicle only) of 97,5%; meanwhile, TMZ (0,9 mg/kg), alone or in combination with morphine, determined a TVI between 84% (TMZ 0,9 mg/kg plus morphine) and 88% (TMZ 0,9 mg/kg), without significant difference between the two groups. No differences in body weight loss were observed comparing control group vs all treated groups (Figure 8B).
Combined treatment with morphine increases long-term response to TMZ
Long-term response to the treatments was evaluated from day +42, end of treatments, until day +84 (all animals were sacrified) (Figure 9A).
Figure 9: Long-term response to TMZ. (A) Images of BLI acquisition of Group 4 (TZM 0,9 mg/kg) and Group 5 (TZM 0,9 mg/kg plus morphine) of the Second Step Experiment, at day +42 (end of treatment) and day+ 84 (sacrifice). BLI is expressed as a total radiance in photons per sec/cm2 per steradian. The colorimetric scale represents the range of radiance values (red=highest value; blu=lowest value) which translates to tumor growth. (B) BLI Average radiance curves distinctly for group of treatment and days of treatment. TMZ (0,9 mg/kg) shows an important effect in combination with morphine (10 mg/kg), determining a BLI reduction of 7,8 fold compared to BLI measured in group treated with only TMZ (0,9 mg/kg). Data were expressed as mean ± SD. (C) Comparison of TMZ (0,9 mg/kg) alone or in combination with morphine (10 mg/kg) at day +84 vs vehicle, showed a significant reduction of BLI of combination TMZ (0,9 mg/kg) plus morphine (10 mg/kg) (*p<0,05) while TMZ (0,9 mg/kg) is not statistically significant. Data were expressed as mean ± SD.
At the end of the treatments, TMZ (1.77 mg/kg) showed a TVI of 97,5%; this inhibition persists for the whole experimental period and reaches up to over 100% (day +84).
The combination TMZ 0,9 mg/kg plus morphine maintained a more or less stable reduction after the end of the treatments until the day +84 with a TVI of 97,3% while, the effect of TMZ 0.9 mg/kg alone ended after the end of treatments (TVI from 88% to 79%, day +42 and +84 respectively). In accordance, the BLI Average Radiance of TMZ 0,9 mg/kg plus morphine group was 7.8 fold lower than value measured in group treated with only TMZ 0.9 mg/kg (Figure 9B) and, at day +84, statistical significant difference were observed comparing BLI data of co-treated group vs control group (*p<0,05) (Figure 9C).
As control, animals were treated with morphine alone; in this case morphine administration does not determine any tumor volume variation compared to animals treated with the vehicle at the end of the treatments (day +42). Conversely, we found a 90,7% of TVI at day +84, but we have to underline that this effect could be due to the lower number of animals survived in this group.
DISCUSSION
Currently adjuvant treatment of GBM is based on the association of RT and TMZ administrations [3].
However, chemoresistance and TMZ-induced side effects (anemia, lymphopenia, neutropenia, severe thrombocytopenia [3, 28, 29, 30] and liver injury [31, 32]) represent a big challenge in the management of oncological patients.
The development of combination therapy that could sensitize GBM to TMZ is essential so, the aim of the present study was investigate the potential of an innovative combinational approach with morphine to improve chemotherapy effectiveness, reducing drug dosage and consequently TMZ-induced side effects.
Morphine is the most used drug for the pain management in oncological patients but, literature data regarding the effect of the opioid agent on tumor cells growth are numerous and controversial [22, 23, 24, 25, 26]
On the other hand, in vivo studies have suggested that stress associated with high doses morphine administration or withdrawal can influence the BBB function [17, 33, 34] and allow the accumulation and the efficacy of anticancer drugs [21].
Judging from all these facts, we first investigated the effect of morphine treatments on GBM tumor cells growth. Our in vitro results showed that exposure to micromolar concentrations of morphine not influenced cells growth (Figure 1), indicating that this agent don’t represent a proliferative stimulus for the tested GBM cells.
To well understand the molecular mechanism underlying the effect of morphine on BBB permeability, we have further investigated the possible interaction between the opioid agent and the efflux protein P-gp, overexpressed in the endothelial cells of the BBB and involved in resistance to many chemotherapeutic drugs.
For the first time, our in vitro results demonstrated that morphine is an effective P-gp inibhitor (Figure 2B), suggesting that the opioid agent could enhances the effects of chemotherapeutic drugs in brain tissue through reduction of the ATP binding cassette transporter function.
Based on the in vitro data acquired in this study and experimental and clinical literature suggesting a key role for P-gp in GBM resistance to TMZ [8, 9], we determined to evaluate the efficacy of combination of morphine with TMZ metronomic treatment in an in vivo model of GBM.
First step experiment data have indicated that morphine treatment is not associated with an increased tumor growth compared to control group (Figure 4) and also that TMZ 1.77mg/kg metronomic treatment, with or without morphine, is effective in tumor growth inhibition from early administrations and not only at the end of the experiment as cumulative doses effect (Figure 5).
However, analyzing the global trend of tumor regression it was possible to appreciate the important effect that TMZ showed in combination with morphine. At day +42, the BLI Average Radiance of TMZ plus morphine group was 2.5 fold lower than value measured in group treated with only TMZ (Figure 6). Moreover, this improvement in antitumor activity of TMZ plus morphine treatment was not associate to an increased systemic toxicity, evaluated as difference in body weight loss between co-treated group and all other groups (Figure 7).
This data encouraged us to test if the combination with morphine could make possible a further reduction of TMZ dosage, with additional benefits in terms of side effects.
Co-treatment with TMZ (1,77 and 0,9 mg/kg), with or without morphine, determined an important tumor growth inhibition, TMZ (1,77 mg/kg) showed a TVI of 97,5% meanwhile, TMZ (0,9 mg/kg), alone or in combination with morphine, determined a tumor reduction between 84% and 88%.
Moreover, from day +42 until day +84, we observed that while the effect of the half dose of TMZ alone ended after the end of treatments, the combination of half dose of TMZ plus morphine maintained a more or less stable reduction from the end of the treatments until the day +84, with a TVI of 97,3%.
As reported in Figure 9B, BLI values of TMZ 0.9 mg/kg, with or without morphine, started from the same point (day+42) but, while BLI values of TMZ 0.9 mg/kg group increased, the BLI values of TMZ 0.9 mg/kg plus morphine group remained stable over the time reaching, at day +84, a BLI fold decrease of 7.8 compared to TMZ 0.9 mg/kg group.
The cytostatic effect of the co-treatment was further supported comparing BLI values of this group vs control group. In Figure 9B can be observed that both treatments curves are below the control but, at the end of the experiment, there was a statistical significant difference (*p<0,05) in tumor volumes only between control and TMZ 0.9 mg/kg plus morphine groups (Figure 9C).
In conclusion, our results demonstrated that morphine is a P-gp inhibitor, TMZ metronomic treatment are effective in GBM therapy and also that combination TMZ plus morphine shows an increased effectiveness in tumor growth inhibition and long term response in a GBM xenograft model.
More study are necessary to well understand the appropriate schedule of co-treatment but, this safe and non-invasive approach could be a successful strategy to overcome chemoresistance and side effects TMZ mediated.
MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance with the ethical standards and according to the Declaration of Helsinki and according to national and international guidelines and has been approved by the authors’ institutional review board.
Drugs and reagents
TMZ (Sigma Aldrich) dissolved in sterile H2O was administered, at different concentrations, per os (p.o.) in a volume of 5 ml/kg. Morphine (Molteni & C s.p.a.) 10 mg/kg was dissolved in sterile saline and subcutaneously (sc) administered in a volume of 5 ml/kg. All chemicals and solvents were of the highest purity available from commercial sources and used without further purification.
MTT assay
The effect of morphine on tumor cells growth was measured using the MTT assay (in vitro toxicology assay kit MTT based, Sigma). The key component of this assay is (3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl tetrazolium bromide), a yellow salt that mitochondrial dehydrogenases of viable cells convert into purple formazan crystals, whose concentration is measured spectrophotometrically. We have conducted preliminary experiments to determine the best seeding concentration for U87MG and A172 cells. Consequently, cells were seeded at the following densities: A172, 6x104 cells/well and U87MG, 4x104 cells/well in 24-well plates. After 24 hours, the cells were treated morphine 10, 20 and 40 μM for 24 and 48 hours. The MTT assay was performed following the manufacturer’s instructions. The plates were placed on a shaker for 10 minutes to enhance solubilization of the precipitate. The absorbance of each well was then measured on a MULTISKAN FC (Thermo Scientific) microplate reader at a test wavelength of 550 nm. All experiments were performed tree times in triplicate
Adenosine triphosphatase (ATPase) assay of P-gp
The ATPase activities of P-gp were determined using the luminescent ATP detection kit (Pgp-Glo Assay Systems, Promega, Madison, WI) according to the manufacturer’s instructions. Briefly, 1.25 mg/mL P-gp membranes and 25 mM MgATP were incubated in absence or presence of morphine, at 37 °C for 40 minutes. The relative lights units (RLU), representing the luciferase-generated luminescent signal, were detected on a plate-reading luminometer (The GloMax® 96 Microplate Luminometer, Promega).
RLU of each sample was interpolate with RLU of ATP standards to obtain ATP concentrations in control (NT) and test compounds (TC). The impact of TC on P-gp ATPase activity was examined comparing NT and samples treated with different concentrations of morphine to Na3VO4 (sodium orthovanadate)-treated control and Verapamil-treated control, that are respectively an inhibitor and a stimulator of the P-gp activity.
Basal P-gp ATPase activities were determined as the difference between the ATP hydrolysis in presence or absence of Na3VO4,
Verapamil and morphine-stimulated P-gp ATPase activity was measured in presence of varying concentrations of morphine,
All experiments were performed two times in triplicate.
Animals
A total of 136 Foxn1 nude mice have been used in this study. The procedure of animals accommodation and care have been described in detail previously [21].
Briefly, 6- to 7-weeks-old nude female mice Foxn1, weighing approximately 21-28 g, were housed inside polysulfone cages (4-5 mice/cage) with stainless steel cover-feed and sterilized and dust-free bedding cobs. Mice were maintained in cages with paper filter covers; food and bedding were sterilized. All manipulations were carried out according to the European Community guidelines for animal care (DL 116/92, application of the European Communities Council Directive 86/609/EEC). Animals were inspected throughout experiments for mortality. Physical appearance, behaviour, general and local clinical signs were also observed; all efforts were made to minimize animal sufferings and mice showing clinical signs of pain and distress were sacrificed for humane reasons by CO2 inhalation. At the end of experiments, all mice were sacrificed by CO2 inhalation.
Tumor implantation
U87MG-luc2 (PerkinElmer Italia S.P.A., Monza, Italy), a human GBM cell line stably transfected with firefly luciferase gene (luc2), was used to establish the orthotopic glioma model.
Cells were cultured in Eagle’s Minimum Essential Medium containing heat-inactivated FBS at final concentration 10% and maintained in a humidified atmosphere of 5% CO2-95% air at 37°C. On the day of the tumor implantation mice were micro-injected with 3x105 U87MG-luc2 cells, suspended in 5 μl of saline solution, in the left lobe of brain with infusion of 1 μl/min (with Hamilton syringe).
Following intracranial tumor injection, BLI acquisitions were performed, at day 0, 3 and 7, for baseline data.
Experimental design
After tumor implantation (day +7), mice were sorted on the basis of BLI Average Radiance and randomly allocated as follows.
Pilot experiment:
Group 1 (Ctr): naïve mice received physiological solution (5 ml/kg). Group 2 (TMZ 1,77 mg/kg): daily administrations from day 7 to 37. Group 3 (TMZ 2,66 mg/kg): daily administrations from day 7 to 37. Group 4 (TMZ 4 mg/kg): daily administrations from day 7 to 37.
Each experimental group contained 7 animals. Tumor growth and weight were carried out weekly and biweekly respectively, for five weeks.
First step experiment:
Group 1 (Ctr): naïve mice received physiological solution (5 ml/kg).
Group 2 (morphine): morphine weekly administrations (days 7, 14, 21, 28, 35).
Group 3 (TMZ 1,77mg/kg): TMZ daily administrations from day 7 to 42.
Group 4 (TMZ 1,77 mg/kg+morphine): weekly administrations of morphine and daily administrations of TMZ.
Each experimental group contained 10 animals. Tumor growth and weight were carried out weekly and biweekly respectively, for five weeks.
Second step experiment:
Group 1 (Ctr): naïve mice received physiological solution (5 ml/kg).
Group 2 (morphine): morphine weekly administrations (days 7, 14, 21, 28, 35). Group 3 (TMZ 1,77 mg/kg): TMZ daily administrations from day 7 to 42.
Group 4 (TMZ 0,9 mg/kg): daily administrations of TMZ from day 7 to 42.
Group 5 (TMZ 0,9 mg/kg+morphine): weekly administrations of morphine and daily administrations of TMZ.
Each experimental group contained 10 animals. Tumor growth and weight were carried out weekly and biweekly respectively, for five weeks. Animals of each groups were observed from day +42 (end of treatments) until the day +84 for long-term response evaluation.
Bioluminescence acquisition
Tumor growth and response to the treatments were monitored by BLI acquisitions, using IVIS 200 Spectrum Imaging System (PerkinElmer). BLI acquisitions were performed at day 0, 3, 7 and then weekly until the end of experiments.
In detail, mice were i.p. administered with 150 mg/kg/10 mL of Dluciferin (PerkinElmer, Xenolight D-Luciferin Potassium Salt, 1g, #122799, batch K9906PE, stored at -20°C) and, 30 minutes upon luciferin administration, were anesthetized by gas anesthesia (3% isoflurane for induction, 1.5% for maintaining). All animals were placed into the IVIS 200 Imaging System to be imaged. BLI was expressed as Average Radiance in photons per sec/cm2 per steradian.
Body weight
Body weight (BW) variation was calculated as follows: [(actual BW (g) x 100) / initial BW (g)] – 100. Measurements were carried out biweekly and, as humane endpoint, animals showing a BW reduction ≥ 15% were sacrificed by CO2 inhalation.
Statistical analysis
Data were expressed as mean ± SD. Statistical analyses were performed using U-Test between two groups while comparison between multiple groups were performed using 1 or 2 way ANOVA followed by post hoc corrections, as appropriate. All analyses were done using GraphPad Prism 5 and P<0,05 was considered statistically significant.
ACKNOWLEDGMENTS
We are grateful to Tommaso Mello, Ph.D., University of Florence, Italy, for his skillful technical assistance.
CONFLICTS OF INTEREST
The authors declare that they have no conflicts of interest.
FUNDING
This work was supported by: Associazione Italiana per la Ricerca sul Cancro (AIRC), grant IG–12799, “Amicodivalerio” Onlus, “Noi per Voi” Onlus and Fondazione Tommasino Bacciotti Onlus.
REFERENCES
1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007; 21: 2683-2710.
2. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006; 1: 97-117.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10: 459-466.
5. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000; 6: 2585-2597.
6. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, Fisher J, Consortium NC. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010; 16: 2443-2449.
7. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003.
8. Munoz JL, Walker ND, Scotto KW, Rameshwar P. Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. Cancer Lett. 2015; 367: 69-75.
9. Munoz JL, Rodriguez-Cruz V, Greco SJ, Nagula V, Scotto KW, Rameshwar P. Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells. Mol Cancer Ther. 2014; 13: 2399-2411.
10. Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol. 2009; 20: 175-181.
11. Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol. 2005; 76: 22-76.
12. Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res. 2009; 15: 7092-7098.
13. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, Stupp R. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res. 2004; 10: 3728-3736.
14. Kim JT, Kim JS, Ko KW, Kong DS, Kang CM, Kim MH, Son MJ, Song HS, Shin HJ, Lee DS, Eoh W, Nam DH. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep. 2006; 16: 33-39.
15. Kong DS, Lee JI, Kim WS, Son MJ, Lim DH, Kim ST, Park K, Kim JH, Eoh W, Nam DH. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep. 2006; 16: 1117-1121.
16. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000; 60: 1388-1393.
17. Sharma HS, Ali SF. Alterations in blood-brain barrier function by morphine and methamphetamine. Ann N Y Acad Sci. 2006; 1074: 198-224. https://doi.org/10.1196/annals.1369.020.
18. Sardi I, la Marca G, Cardellicchio S, Giunti L, Malvagia S, Genitori L, Massimino M, de Martino M, Giovannini MG. Pharmacological modulation of blood-brain barrier increases permeability of doxorubicin into the rat brain. Am J Cancer Res. 2013; 3: 424-432.
19. Sardi I, la Marca G, Giovannini MG, Malvagia S, Guerrini R, Genitori L, Massimino M, Arico M. Detection of doxorubicin hydrochloride accumulation in the rat brain after morphine treatment by mass spectrometry. Cancer Chemother Pharmacol. 2011; 67: 1333-1340.
20. Sardi I. Morphine facilitates doxorubicin penetration in the central nervous system: a new prospect for therapy of brain tumors. J Neurooncol. 2011; 104: 619-620.
21. da Ros M, Iorio AL, Consolante D, Cardile F, Muratori M, Fantappie O, Lucchesi M, Guidi M, Pisano C, Sardi I. Morphine modulates doxorubicin uptake and improves efficacy of chemotherapy in an intracranial xenograft model of human glioblastoma. Am J Cancer Res. 2016; 6: 639-648.
22. Amini-Khoei H, Hosseini MJ, Momeny M, Rahimi-Balaei M, Amiri S, Haj-Mirzaian A, Khedri M, Jahanabadi S, Mohammadi-Asl A, Mehr SE, Dehpour AR. Morphine attenuated the cytotoxicity induced by arsenic trioxide in H9c2 cardiomyocytes. Biol Trace Elem Res. 2016; 173: 132-139.
23. Cao LH, Li HT, Lin WQ, Tan HY, Xie L, Zhong ZJ, Zhou JH. Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts. Sci Rep. 2016; 6: 18706.
24. Lazarczyk M, Matyja E, Lipkowski AW. A comparative study of morphine stimulation and biphalin inhibition of human glioblastoma T98G cell proliferation in vitro. Peptides. 2010; 31: 1606-1612.
25. Bimonte S, Barbieri A, Rea D, Palma G, Luciano A, Cuomo A, Arra C, Izzo F. Morphine promotes tumor angiogenesis and increases breast cancer progression. Biomed Res Int. 2015; 2015: 161508.
26. Ge ZH, Wang ZX, Yu TL, Yang N, Sun Y, Hao CL, Sun LX. Morphine improved the antitumor effects on MCF-7 cells in combination with 5-Fluorouracil. Biomed Pharmacother. 2014; 68: 299-305.
27. Kim JY, Ahn HJ, Kim JK, Kim J, Lee SH, Chae HB. Morphine suppresses lung cancer cell proliferation through the interaction with opioid growth factor receptor: an in vitro and human lung tissue study. Anesth Analg. 2016; 123: 1429-1436.
28. Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, Bahr O, Meyermann R, Bamberg M, Tatagiba M, von Deimling A, Weller M, Wick W. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys. 2010; 77: 670-676.
29. Niewald M, Berdel C, Fleckenstein J, Licht N, Ketter R, Rube C. Toxicity after radiochemotherapy for glioblastoma using temozolomide--a retrospective evaluation. Radiat Oncol. 2011; 6: 141.
30. Dixit S, Baker L, Walmsley V, Hingorani M. Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review. Anticancer Drugs. 2012; 23: 1099-1106.
31. Grieco A, Tafuri MA, Biolato M, Diletto B, Di Napoli N, Balducci N, Vecchio FM, Miele L. Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature. Medicine (Baltimore). 2015; 94: e476.
32. Aygun C, Altinok AY, Cakir A, Agan AF, Balaban Y. Acute temozolomide induced liver injury: mixed type hepatocellular and cholestatic toxicity. Acta Gastroenterol Belg. 2016; 79: 487-489.
33. Sharma HS, Sjoquist PO, Ali SF. Alterations in blood-brain barrier function and brain pathology by morphine in the rat. Neuroprotective effects of antioxidant H-290/51. Acta Neurochir Suppl. 2010; 106: 61-66.
34. Afsharimani B, Cabot P, Parat MO. Morphine and tumor growth and metastasis. Cancer Metastasis Rev. 2011; 30: 225-238.
